摘要
纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)作为体内组织型纤溶酶原激活物(tissue-type plasminogen activator,t-PA)和尿激酶型纤溶酶原激活物(urokinase-type plasminogen activator,u-PA)的主要抑制剂,与动静脉血栓、出血和凝血异常、细胞迁移密切相关,进而引起缺血性脑卒中、冠心病、静脉血栓、肿瘤转移、出血、股骨头坏死、流产等一系列疾病的发生发展。同时,体内血浆PAI-1活性水平又受血脂、血糖等调节,进一步参与肥胖、糖尿病、高脂血症等疾病的进程,又影响着上述相关疾病的预后。
Plasminogen activator inhibitor 1(PAI-1),as the main inhibitor of tissue-type plasminogen activator(t-PA)and urokinase-type plasminogen activator(u-PA)in body,is closely related to arteriovenous thrombosis,abnormal coagulation and cell migration,which further leads to the occurrence and development of a series of diseases including ischemic stroke,coronary heart disease,venous thrombosis,tumor metastasis,hemorrhage,femoral head necrosis and abortion.Meanwhile,the level of plasma PAI-1 in the body is regulated by blood lipids and blood glucose,which further involves obesity,diabetes,hyperlipidemia and other diseases,and affects the prognosis of the above-mentioned related diseases.PAI-1 research covers a wide range of areas.
作者
蔡雪蓉
张学亚
潘敬新
CAI Xuerong;ZHANG Xueya;PAN Jingxin(Department of Hematology,Second Affiliated Hospital of Fujian Medical University,Fuzhou 362000,China)
出处
《临床与病理杂志》
2020年第2期458-463,共6页
Journal of Clinical and Pathological Research
基金
福建省母婴健康应用技术创新课题(XJM1805)~~
